Filter By Category
Archives
Share on -
AVATROMBOPAG
Generic Name: AVATROMBOPAG
ABSTRACT -
Avatrombopag is an oral small-molecule thrombopoietin receptor agonist used where approved to raise platelet counts in selected thrombocytopenia settings. Its molecular formula is C₂₉H₃₄Cl₂N₆O₃S₂. The chemical representation above shows the 2D skeletal structure.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- Use only according to the approved local product label for the specific indication.
- Dose, duration, and monitoring requirements may differ by disease, organ function, age, and interacting medicines.
- Do not change, stop, or restart treatment without medical supervision.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Headache, fatigue, fever, nausea, abdominal pain, or edema
- Thromboembolic events may occur if platelet counts rise excessively or risk factors are present
- Liver function abnormalities can occur in susceptible patients
- Rash, pruritus, or hypersensitivity symptoms are possible
- Underlying disease complications may overlap with drug effects
ALLERGIC REACTIONS -
Hypersensitivity to Avatrombopag or related compounds/products may occur. Symptoms may include:
- Immediate urticaria, itching, flushing, or generalized rash
- Facial, lip, tongue, or throat swelling
- Wheezing, chest tightness, or breathing difficulty
- Dizziness, fainting, severe hypotension, or collapse
- Anaphylaxis, although uncommon, requires emergency medical treatment
Important: Patients who develop an allergic reaction to Avatrombopag should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
Avatrombopag may interact with certain medicines, biologics, vaccines, protocols, or clinical conditions. Caution is needed with:
- Anticoagulants and antiplatelet medicines require careful coordination.
- Other thrombopoietic agents may increase platelet-response risk.
- Medicines affecting hepatic transport/metabolism may alter exposure.
- Patients should report all medicines, supplements, and herbal products.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Monitor platelet counts according to indication and label.
- Use caution in patients with thrombotic risk or chronic liver disease.
- Do not normalize platelet counts beyond the treatment goal.
- Pregnancy and lactation require individualized medical review.
WARNINGS –
- Thrombosis can occur; monitor for chest pain, shortness of breath, limb swelling, or neurologic symptoms.
- Use only for approved thrombocytopenia settings under medical supervision.
- Do not use to treat myelodysplastic syndromes unless specifically indicated.
- Keep out of reach of children.
Share on -
. Developed by